MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice

BACKGROUND: The Adjuvant Zoledronic Acid (ZA) study in early breast cancer (AZURE) showed correlation between a nonamplified MAF gene in the primary tumor and benefit from adjuvant ZA. Adverse ZA outcomes occurred in MAF-amplified patients. NSABP B-34 is a validation study. METHODS: A retrospective...

Descripción completa

Detalles Bibliográficos
Autores principales: Paterson, Alexander H G, Lucas, Peter C, Anderson, Stewart J, Mamounas, Eleftherios P, Brufsky, Adam, Baez-Diaz, Luis, King, Karen M, Lad, Thomas, Robidoux, André, Finnigan, Melanie, Sampayo, Miguel, Tercero, Juan Carlos, Mairet, Joël Jean, Wolff, Antonio C, Fehrenbacher, Louis, Wolmark, Norman, Gomis, Roger R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346694/
https://www.ncbi.nlm.nih.gov/pubmed/34377934
http://dx.doi.org/10.1093/jncics/pkab054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8346694/
https://www.ncbi.nlm.nih.gov/pubmed/34377934
http://dx.doi.org/10.1093/jncics/pkab054

Ejemplares similares